Skip to main content

Table 1 Patient and tumor characteristics and pattern of failure

From: Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

Variables

SIB group

SeqB group

Total

p-value

Pts N (%)

Pts N (%)

Pts N (%)

 

Sex

 Female

64 (73.6)

76 (73.8)

140 (73.7)

0.9722

 Male

23 (26.4)

27 (26.2)

50 (26.3)

 

Median age (range)

64 (55–70)

62 (53–77)

63 (53–77)

a0.4471

Subsite

 Anal canal

73 (83.9)

80 (77.7)

153 (80.5)

<.0001

 Anal margin

14 (16.1)

23 (22.3)

37 (19.5)

 

Histologic type

 Basaloid

7 (8.0)

7 (6.8)

14 (7.4)

0.7425

 Squamous cell

80 (92.0)

96 (93.2)

176 (92.6)

 

Grading

 NA

2 (2.4)

19 (18.4)

21 (11.1)

 

 G1

7 (8.0)

28 (27.2)

35 (18.4)

0.0003

 G2

57 (65.5)

39 (37.9)

96 (50.5)

 

 G3

21 (24.1)

17 (16.5)

38 (20.0)

 

T stage

 T1

5 (5.8)

4 (3.9)

9 (4.7)

0.0725

 T2

55 (63.2)

57 (55.3)

112 (59.0)

 

 T3

23 (26.4)

25 (24.3)

48 (25.3)

 

 T4

4 (4.6)

17 (16.5)

21 (11.0)

 

N stage

 N0

57 (65.5)

53 (51.5)

110 (57.9)

0.0015

 N1

5 (5.8)

17 (16.5)

22 (11.6)

 

 N2

21 (24.1)

15 (14.6)

36 (18.9)

 

 N3

4 (4.6)

18 (17.4)

22 (11.6)

 

Global stage

 I

5 (5.7)

3 (2.9)

8 (4.2)

0.0730

 II

49 (56.3)

44 (42.7)

93 (48.9)

 

 IIIA

8 (9.3)

21 (20.4)

29 (15.3)

 

 IIIB

25 (28.7)

35 (34.0)

60 (31.6)

 

Inguinal node involv.

 NA

0 (0%)

1 (1)

1 (0.6)

0.0187

 Yes

18 (20.7)

37 (35.9)

55 (28.9)

 

 No

69 (79.3)

65 (63.1)

134 (70.5)

 

Time biopsy-RT (days)

  ≥ 60

62 (71.3)

5 (4.9)

67 (35.3)

0.0172

  < 60

25 (28.7)

98 (95.1)

123 (64.7)

 

OTT (days)

  < 45

62 (71.3)

5 (4.9)

67 (35.3)

<.0001

  ≥ 45

25 (28.7)

98 (95.1)

123 (64.7)

 
  1. aU-Mann Whitney Test
  2. Legend: SIB simultaneous integrated boost, SeqB sequential boost, pts patients, N: number; involv.: Involvement, RT radiotherapy; OTT overall treatment time